KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Inventory (2016 - 2025)

Historic Inventory for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $483.1 million.

  • Jazz Pharmaceuticals' Inventory fell 1041.92% to $483.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $483.1 million, marking a year-over-year decrease of 1041.92%. This contributed to the annual value of $480.4 million for FY2024, which is 1952.87% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Inventory of $483.1 million as of Q3 2025, which was down 1041.92% from $505.0 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Inventory ranged from a high of $1.3 billion in Q2 2021 and a low of $115.5 million during Q1 2021
  • Moreover, its 5-year median value for Inventory was $611.8 million (2023), whereas its average is $685.7 million.
  • In the last 5 years, Jazz Pharmaceuticals' Inventory soared by 125221.54% in 2021 and then plummeted by 3601.32% in 2022.
  • Jazz Pharmaceuticals' Inventory (Quarter) stood at $1.1 billion in 2021, then tumbled by 33.43% to $714.1 million in 2022, then decreased by 16.39% to $597.0 million in 2023, then dropped by 19.53% to $480.4 million in 2024, then rose by 0.55% to $483.1 million in 2025.
  • Its Inventory stands at $483.1 million for Q3 2025, versus $505.0 million for Q2 2025 and $492.8 million for Q1 2025.